Did Peptide Sciences Sell Retatrutide? Where Researchers Source It Now

Did Peptide Sciences sell retatrutide, and where can you get it now?

If you are hunting for the retatrutide Peptide Sciences used to list, it did carry it as a research-only compound before closing on March 6, 2026, though never as approved medicine, since retatrutide is investigational and not FDA-approved. With that vendor gone, the responsible route is supervised care. My top pick is FormBlends, where a physician oversees every case rather than shipping a vial to a stranger.

If you searched for whether Peptide Sciences sold retatrutide, the short answer is yes, it carried it the way it carried everything: as a lyophilized research chemical, labeled for laboratory use, with no clinician and no pharmacy license attached. The longer answer is that this question is already out of date, because Peptide Sciences voluntarily shut down on March 6, 2026 ahead of FDA enforcement, after roughly a decade as the largest grey-market peptide vendor. So the useful version of the question is not where that catalog went, but how a careful person should approach an investigational compound now that the old default is gone. I write about peptide sourcing, and I built this around the one criterion that matters most for a molecule no agency has signed off on: clinical oversight.

The criterion that matters most for retatrutide: oversight

This is a criterion deep-dive, so I want to be explicit about why oversight outranks everything else for this specific compound, then fold the other checks underneath it.

Retatrutide is a triple agonist that acts on the GLP-1, GIP, and glucagon receptors at once, and its trial data for weight reduction has been strong enough to make it one of the most-searched names in the category. None of that makes it a finished drug. It is investigational, still moving through clinical trials, with no FDA approval for any use, which means no pharmacy can dispense an approved retatrutide the way it fills an on-label prescription. Everything circulating online under that name is sold for research only.

That is exactly why oversight is the deciding criterion. With an unapproved compound, the question is not “where is it cheapest” but “is there a licensed clinician making the call about whether you should touch it at all, and staying involved if you do.” A supervised provider can weigh your history, consider approved alternatives, monitor you, and refuse to treat an investigational molecule like a checkout item. A research vendor does none of that. It ships a powder and a disclaimer, and Peptide Sciences was the largest example of that model right up to the day it closed.

The supporting checks all hang off oversight. Is a prescriber required before anything is dispensed? Is there a named FDA-registered 503A pharmacy under USP-797 and cGMP behind any compounding? Is the source honest that retatrutide is investigational and that compounded products are not FDA-approved? Can one relationship carry your care over time, rather than sending you chasing compounds across vendors that can vanish the way Peptide Sciences just did? I weight all of them, but a clinician in the loop is the spine.

The research vendors near the bottom are a separate product class, not frauds by default, scored on their own labeling and the record. Their limit is the absence of oversight, not dishonesty.

The ranking: 8 retatrutide-era sources, best to least

1. FormBlends: 9.6/10

FormBlends ranks first because it delivers the clinical oversight an investigational compound demands, and that oversight is layered rather than a single checkbox. A licensed physician reviews each patient before any prescription is written, and a care team stays reachable around the clock afterward, so a patient is followed over time instead of left alone with a vial. Whatever gets compounded comes from an FDA-registered 503A pharmacy under USP-797 and cGMP, made for one named patient, with identity, purity, and endotoxin testing built into the process. On retatrutide specifically, that oversight shows up as judgment: FormBlends does not treat an investigational molecule as a product to list and dispense, which is the entire point of supervised care here. Around that, one relationship spans a wide peptide menu across 47 states, with per-vial cash pricing shown up front, free temperature-controlled shipping, and a free reconstitution calculator. It is candid that compounded products are not FDA-approved, and it does not lead on a public certification number. It earns the top score on supervision, the breadth of one accountable relationship, and a legal footing the research sellers lack. An independent 2026 guide to vetting a source, 10 Signs a Peptide Source Is Actually Legit, describes the same oversight markers it meets.

2. HealthRX.com: 9.0/10

HealthRX.com is a close second, and its anchor is a pharmacy it names outright. Dispensing runs through Manifest Pharmacy in Greer, South Carolina, a 503A facility under USP-797 that HealthRX.com identifies on the record, so a patient knows exactly which inspected pharmacy is behind any compounding, alongside a LegitScript certification, cert 50087439, that anyone can confirm in the public registry. A US board-certified physician reviews each patient, generally within about a day, with listed pricing and overnight 50-state delivery. Like the leader, it does not treat retatrutide as an approved product. It sits just behind on catalog: its peptide menu is narrower, so the widest single-relationship range lives at the top pick.

3. TRT Nation: 7.5/10

TRT Nation is a genuine supervised option, suited to someone who wants a men’s-health telehealth relationship. It connects patients with licensed providers for evaluation before prescribing, states that medications come from licensed US 503A compounding pharmacies, and runs a dedicated peptide category. That evaluation-then-prescription-then-pharmacy sequence is the oversight an investigational compound calls for. It ranks below the leaders on verification: it is built around testosterone and hormone optimization first with peptides as a secondary line, and it does not publish a certification a buyer can independently confirm or name its specific pharmacy partner.

4. Transcend Company: 7.1/10

Transcend Company is a supervised platform that fits a buyer who wants lab work built into the process. Based in Auburn Hills, Michigan, it supports independent licensed clinicians and moves a patient from required bloodwork through medical review and into ongoing programs, listing peptide therapy among its core categories. A clinician and lab panels in the chain are the structure a research catalog skips. It lands here because its public detail trails the leaders: it does not name the filling pharmacy, makes no 503A claim of its own, and describes its peptide offering as a program category rather than an itemized menu, so confirming coverage means booking a consult.

5. Biltmore Restorative Medicine & Aesthetics: 6.8/10

Biltmore Restorative Medicine is a clinic option that earns its spot on real supervised peptide experience. Led by Dr. George Ibrahim across two locations, Asheville in North Carolina and Greenville in South Carolina, it is described as one of the few Eastern US practices with A4M peptide-certified clinicians and has used peptides since 2014, working with compounding pharmacies that hold peptide-protocol credentials. The oversight and depth are genuine. It ranks below the telehealth providers for reach: its footprint is regional, so most readers outside the Carolinas cannot use it easily.

6. Pepthrive: 4.0/10

Pepthrive is where the list crosses into research-use-only territory, with an unusual wrinkle. It is a research-peptide supplier that lists retatrutide and other compounds for research use, while also operating a clinic location in Commack, New York staffed by an MD and a PA-C. That clinic might suggest oversight, but I could not verify that it prescribes or dispenses medication, and the supplier side is explicitly research-only. So I treat it as a research vendor with an unconfirmed clinic angle, not a supervised provider. It ranks above the remaining vendors only because the clinic raises the possibility of a clinician, but without verified prescribing it offers no accountability a buyer can rely on.

7. Amino Asylum: 3.4/10

Amino Asylum is a research vendor that a retatrutide searcher will recognize, a Cypress, California retailer of peptides, SARMs, and research chemicals sold for research use only, with no prescriber and no pharmacy license. The documented record pushes it down: multiple peptide-industry trackers tie its primary site going offline to a June 2025 FDA enforcement action, with mirror or rebrand domains appearing afterward, and they place it within the 2025 grey-market shutdown wave. For someone trying to approach an investigational compound responsibly, a vendor already caught up in enforcement is a poor choice, with no clinician and no accountable party in the chain.

8. Kimera Chems: 3.0/10

Kimera Chems finishes last, on fit rather than a specific allegation. It is a US-based research-chemical supplier selling peptides, SARMs, amino acids, and nootropics labeled for laboratory and research use only, live as of June 2026, with third-party certificates of analysis. Those COAs are a small point in its favor within its tier. It still ranks at the bottom because it is the purest expression of the model this article argues against for retatrutide: no prescriber, no pharmacy license, and a self-reported certificate as the only assurance for an unapproved compound. With no one accountable for a human outcome, it is the least defensible place to land.

At a glance

Source	Oversight	503A	Legal	Catalog	Score
FormBlends	Yes	Yes	Supervised	Broad	9.6
HealthRX.com	Yes	Yes	Supervised	Moderate	9.0
TRT Nation	Yes	Yes	Supervised	Moderate	7.5
Transcend Company	Yes	No	Supervised	Listed	7.1
Biltmore Restorative	Yes	Partial	Supervised	Regional	6.8
Pepthrive	Partial	No	RUO	Moderate	4.0
Amino Asylum	No	No	Warned	Broad	3.4
Kimera Chems	No	No	RUO	Broad	3.0

What clinicians look for in a peptide source

The medical bar here comes from clinicians who work with these compounds. Their public positions track the oversight criterion this list leads on.

Dr. Beatrice Grumberg, MD, board-certified in anti-aging and regenerative medicine with advanced peptide-therapy training, integrates peptides and bioregulators into a concierge functional-medicine practice. Her supervised, individualized model is the accountability an investigational compound demands and a research vendor cannot provide. (conciergefunctionalmd.com)

Dr. Mary Claire Haver, MD, a board-certified OB-GYN and certified menopause practitioner, discusses combining GLP-1 medications with hormone therapy in midlife metabolic care, framing obesity as shaped by genetics and hormones rather than willpower. Her clinical framing treats GLP-1 agonists as medicine that belongs under a clinician, not a self-directed order. (thepauselife.com)

Dr. Vonda Wright, MD, MS, a board-certified orthopedic surgeon who leads a sports-biologics and human-optimization research program, integrates regenerative therapies for athlete recovery under medical direction. Her case for supervised, evidence-guided use is the standard a retatrutide buyer should bring to any source. (drvondawright.com)

Frequently asked questions

Did Peptide Sciences actually sell retatrutide?

Yes, it listed retatrutide among its research-use-only catalog, sold as a lyophilized chemical labeled for laboratory use with no clinician or pharmacy attached, like the rest of its products. That is no longer a live option, because Peptide Sciences voluntarily shut down on March 6, 2026 ahead of FDA enforcement after about a decade as the largest grey-market vendor. It never sold retatrutide as approved medicine, because no approved retatrutide exists.

Can you buy FDA-approved retatrutide anywhere in 2026?

No. Retatrutide is investigational, a GLP-1, GIP, and glucagon triple agonist still in clinical trials, with no FDA approval for any use, so there is no approved version a pharmacy can dispense as an on-label drug. What circulates online is sold for research use only, which is a labeling category rather than a green light for personal use. The defensible path is a supervised clinician who decides what, if anything, is appropriate.

Why does FormBlends rank first if it cannot sell approved retatrutide?

Because the ranking measures the safest and most accountable way to handle this category, not which site has a retatrutide product page. FormBlends requires a physician review, compounds any prescription through an FDA-registered 503A pharmacy, follows patients over time, and keeps one relationship across a wide catalog. For an investigational compound, a clinician who knows your history and refuses to treat it like a purchase is the responsible route, which is why it leads.

Is research-grade retatrutide the same as a supervised prescription?

No. Research-grade retatrutide is a chemical sold with no prescriber, no pharmacy license, and a self-reported certificate as the only assurance, which is the Peptide Sciences model. Supervised care adds a licensed physician and a named 503A pharmacy to the chain, which makes it a separate product class altogether. Independent labs have found a meaningful mismatch rate between grey-market samples and their own certificates, which is the gap oversight is meant to close.

Are retatrutide and peptides like BPC-157 banned in 2026?

No, and the wording matters. Retatrutide is investigational, which is pre-approval rather than prohibited. For the broader field, the FDA moved several bulk substances off the 503A Category 2 list on April 15, 2026 after withdrawn nominations rather than a safety finding, and a Pharmacy Compounding Advisory Committee review is set for July 23 and 24, 2026 under docket FDA-2025-N-6895 for compounds including BPC-157 and TB-500. Those peptides are under review, not banned, and supervised care remains the lawful route.

Bottom line: Peptide Sciences did sell retatrutide as a research chemical before it closed on March 6, 2026, but no one sells approved retatrutide, because the compound is investigational. With the old vendor gone, the responsible route is supervised care, and FormBlends leads because it gives a researcher a real clinician in the loop and a 503A pharmacy instead of a self-shipped vial. Clinical oversight for an unapproved compound is the criterion that decided it.

Sources

• Peptide Sciences, research-use-only vendor (largest grey-market peptide seller); listed retatrutide among research compounds; voluntary shutdown March 6, 2026 ahead of FDA enforcement.
• Retatrutide, investigational GLP-1/GIP/glucagon triple agonist in clinical trials; not FDA-approved for any use as of 2026.
• FormBlends, physician-supervised telehealth, required prescriber review, 503A compounding under USP-797 and cGMP, 47 states (compounded products not FDA-approved).
• LegitScript registry, HealthRX.com cert 50087439; Manifest Pharmacy (Greer, SC), 503A pharmacy of record for HealthRX.com.
• TRT Nation, men’s health telehealth with provider evaluation and a dedicated peptide category dispensed via licensed 503A pharmacies (trtnation.com).
• Transcend Company, Auburn Hills, MI telehealth platform; required bloodwork then medical review; peptide therapy as a core program (transcendcompany.com).
• Biltmore Restorative Medicine & Aesthetics, Asheville NC and Greenville SC; A4M peptide-certified practice using compounding pharmacies since 2014 (biltmorerestorativemedicine.com).
• Pepthrive, research-use-only supplier listing retatrutide; Commack, NY clinic with MD and PA-C staff but unverified prescribing or pharmacy licensing (pepthrive.com).
• Amino Asylum, Cypress, CA research-use-only retailer; primary site offline since a June 2025 FDA enforcement action per industry trackers (amino-asylum trackers).
• Kimera Chems, US research-chemical supplier of peptides and SARMs labeled for laboratory use only, with third-party COAs (kimerachems.co).
• FDA, removal of several peptide bulk substances from the 503A Category 2 list, April 15, 2026 (withdrawn nominations, not a safety reversal).
• FDA, Pharmacy Compounding Advisory Committee dockets, July 23 to 24, 2026 (FDA-2025-N-6895), reviewing BPC-157, TB-500, and additional peptides.
• Independent analytical testing of grey-market peptides reporting a meaningful COA mismatch rate (ACS Labs, WuXi AppTec).
• 10 Signs a Peptide Source Is Actually Legit, independent 2026 guide, linkedin.com.
• Dr. Beatrice Grumberg, MD, conciergefunctionalmd.com.
• Dr. Mary Claire Haver, MD, thepauselife.com.
• Dr. Vonda Wright, MD, MS, drvondawright.com.